SRTS Overview

Sensus Healthcare, Inc. is a medical device company. The Company is engaged in the development and delivery of non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is incorporated into a portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT technology is used to effectively and safely treat oncological and non-oncological skin conditions. The SRT-100 is a photon x-ray low-energy SRT system that provides patients with an alternative to surgery for treating NMSC, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with an SRT-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and comprehensive dosimetry parameters.

Wall Street analysts forecast SRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTS is7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sensus Healthcare Inc revenue for the last quarter amounts to 3.39M USD, decreased -59.32

Sensus Healthcare Inc. EPS for the last quarter amounts to -0.16 USD, decreased -0.00

Sensus Healthcare Inc (SRTS) has 60 emplpoyees as of June 06 2026.

Today SRTS has the market capitalization of 44.45M USD.